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Purpose: Composite neuroendocrine-exocrine carcinomas are malignancies that have two distinct components residing within the same 
tumor: an adenocarcinomatous portion and a neuroendocrine portion. This is rare in gastric cancers; however, poorly differentiated ad-
enocarcinomas can sometimes reveal evidence of neuroendocrine features (NEF) or be ‘mixed endocrine and exocrine carcinomas’. This 
study aimed to review NEF in gastric adenocarcinoma and to evaluate its prognostic significance.
Materials and Methods: We selected 29 patients who were diagnosed with gastric adenocarcinoma with NEF and received gastrecto-
mies at the Department of Surgery, Ajou University Hospital between January 2001 and December 2009. We analyzed the clinicopath-
ologic features of gastric cancer with NEF and the prognosis associated with such tumors.
Results: The pathologic result with respect to TNM staging of the gastric cancers with NEF were as follows: 5 cases of T1, 5 cases of 
T2, 10 cases of T3, and 9 cases of T4. There were 7 cases of N0, 7 cases of N1, 8 cases of N2 and 7 cases of N3. The staging of 
patients with NEF was higher than that of patients without NEF. Especially tumor lymphovascular invasion rate was 82.8%. The overall 
survival of patients with gastric cancer characterized by NEF was 73.8 months.
Conclusions: Positive NEF status might be correlated with clinicopathologic parameters such as a high stage and high frequency of re-
gional lymph node metastasis.
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Introduction
Neuroendocrine tumors originating from diffuse neuroendo-
crine cells are only partially classified under the same scheme, 
while in part follows the classification of the tumors of the specific 
site of origin (i.e., in the respiratory and urogenital tract); such 
almost contradictory state of affairs concerns also the group of 
mixed neuroendocrine and non-neuroendocrine neoplasms.(1) 
Neuroendocrine tumors may give rise to pure endocrine tumors or 
neoplasms that have aspects of both neuroendocrine differentiation 
and non-neuroendocrine features.(2)
Gastric epithelial tumors that are composed of exocrine cells 
and neuroendocrine cells can be divided into two broad groups: 
pure endocrine tumors, i.e., adenomas or adenocarcinomas with 
interspersed neuroendocrine cells, and typical endocrine tumors, i.e., 
mixed exocrine-neuroendocrine tumors in which neuroendocrine 
components represent at least one-third to half of the tumor tissue.
(2-4) Both ‘pure or typical’ carcinomas are rare in gastric cancer. 
However, sometimes gastric adenocarcinomas show evidence of 
‘neuroendocrine features (NEF)’ or act as ‘mixed endocrine and 
exocrine carcinomas’.(1)
Histological differentiation of gastric cancer has long been ac-
cepted as one of the indicators of prognosis. More specifically, the 
degree of tumor cell differentiation correlates with neoplasm ag-Kim JJ, et al.
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gressiveness.(5-8) However, there have been few studies concern-
ing the correlation between NEF and disease progression.
This study aimed to review NEF in gastric adenocarcinoma and 
to evaluate the prognostic significance of this diagnosis.
Materials and Methods
1. Patient population
We selected 29 patients who were diagnosed gastric adenocar-
cinoma with NEF and who received a gastrectomy at the Depart-
ment of Surgery, Ajou University Hospital between January 2001 
and December 2009. We retrospectively collected data using medi-
cal records and telephone interviews. We analyzed patient’s age, 
gender, tumor location, gross findings, tumor size, cancer stage, 
pathologic classification (i.e., Lauren classification, lymphatic or 
vascular invasion) and overall survival.
2. Diagnosis of neuroendocrine feature
All tumors were fixed with 10% formalin and embedded in 
paraffin immediately after resection. They were then stained with 
Table 1. Clinicopathological characteristics of the gastric adenocarcinoma with neuroendocrine features (NEF)
No Age Sex Location Gross type Size (cm) T stage N stage Stage
1 69 F Lower B-III 10 T4b N3a IIIc
2 72 M Lower B-II 5 T3 N1 IIb
3 80 M Lower B-II 5.5 T4a N0 IIb
4 65 M Lower EGC IIa 3 T1a N0 Ia
5 59 M Lower B-III 6 T3 N1 IIb
6 57 M Middle B-II 3 T2 N2 IIb
7 54 F Lower B-III 4 T3 N2 IIIa
8 49 M Lower B-III 2.5 T4a N3b IIIc
9 77 M Middle B-II 12 T3 N2 IIIa
10 50 M Lower EGC IIb+IIc 3.5 T1a N0 Ia
11 53 M Lower B-II 3.5 T2 N1 IIa
12 43 M Lower B-III 7.5 T4a N3b IIIc
13 48 F Upper B-II 5.3 T3 N1 IIb
14 30 F Middle B-III 4.5 T2 N3a IIIa
15 59 M Lower B-I 4.5 T3 N2 IIIa
16 66 M Lower EGC IIb+IIc 2.5 T1b N2 IIa
17 50 M Upper B-II 8.5 T4a N1 IIIa
18 51 M Lower B-III 7 T4a N3b IIIc
19 64 M Lower B-III 5 T3 N2 IIIa
20 52 M Lower B-III 5 T3 N1 IIb
21 76 M Middle B-III 3.5 T4a N3b IIIc
22 62 M Lower B-III 2.8 T2 N2 IIb
23 31 M Middle B-II 5.5 T4a N2 IIIb
24 63 F Lower EGC IIb+IIc 2.5 T1b N0 Ia
25 69 F Lower B-III 7.5 T3 N0 IIa
26 50 M Lower B-III 4 T3 N0 IIa
27 40 M Middle B-IV 4.5 T4a N0 IIb
28 69 M Lower EGC IIc 2 T1b N1 Ib
29 74 M Lower B-III 2.5 T2 N3b IIIa
Tumor (T) and node (N) were defi  ned as described in the seventh edition of the American Joint Committe on Cancer classifi  cation of gastric 
carcinomas. M = male; F = female; B = Borrmann; EGC = early gastric cancer.Adenocarcinoma with Neuroendocrine Features
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hematoxylin and eosin and evaluated with respect to the histologi-
cal classification of the lesion. When the tumor consisted of both 
neuroendocrine and adenocarcinomatous components juxtaposed 
within the individual tumor and the neuroendocrine components 
occupied at least 30% of the tumor tissue, we diagnosed NEF in 
the adenocarcinoma. Following this, we performed additional im-
munohistochemistry of the NEF tumor. NEF stained a particular 
color when stained with chromogranin A or synaptophysin. 
3. Follow-up and statistical analysis
Outcomes were determined by tumor location, tumor size, 
pathologic stage, local invasion and disease progression. The over-




There were 23 men and 6 women who were enrolled in the 
study with NEF of the gastric adenocarcinoma. The mean age of 
the sample was 58 years old (range: 30 to 80 years old). The tumor 
size ranged from 2.0 to 12.0 cm in maximal diameter, with a me-
dian of 4.5 cm. Two of the tumors were situated in the upper third; 
six tumors were situated in the middle third; and twenty-one were 
situated in the lower third. According to the Borrmann gross type 
classification, there was 1 Borrmann type I case, 8 Borrmann type 
II cases, 14 Borrmann type III cases, 1 Borrmann type IV case and 
5 early gastric cancer cases. The pathologic result of gastric cancer 
with NEF was classified using the tumor-nod-metastasis (TNM) 
staging system. There were 5 T1 cases, 5 T2 cases, 10 T3 cases, 8 
T4a cases, and 1 T4b case. There were 7 N0 cases, 7 N1 cases, 8 
N2 cases, 2 N3a cases and 5 N3b cases. Finally, there were 4 stage 
I cases (13.8%), 12 stage II cases (41.4%), and 13 stage III cases 
(44.8%) (Table 1).
2. Histological finding
On histological examination, lymphatic invasion was evident in 
24 cases (82.8%), vascular invasion was evident in 17 cases (58.6%) 
Fig. 1. Histological fi  nding of H&E stain and immunohistochemis-
try. (A) Adenocarcinoma with neuroendocrine features (H&E stain, 
×200). (B) Positive in area of neuroendocrine tumor (Gold color) 
(Synaptophysin stain, ×200). (C) Positive in area of neuroendocrine 
tumor (Gold color) (Chromogranin A stain, ×200).Kim JJ, et al.
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and neural invasion was evident in 11 cases (37.9%). By Lauren 
classification, there were 12 diffuse-type cases (41.4%), 13 intesti-
nal-type cases (44.8%), 4 mixed-type cases (13.8%) (Table 2).
After we diagnosed NEF, sometimes we subsequently per-
formed additional Chromogranin A and synaptophysin immu-
nohistochemical staining. Chromogranin A was performed on 16 
cases, and 10 tumors (62.5%) were positive for chromogranin A. 
Synaptophysin was performed on 17 cases, and 13 tumors (76.5%) 
were positive for synaptophysin (Fig. 1).
3. Treatment outcomes
All patients were treated using gastrectomy with lymph node 
dissection adopted by adenocarcinoma in gastric cancer. If the 
final pathologic stage of the tumor was greater than stage II, we 
performed adjuvant chemotherapy. No patients had post-operative 
mortality or critical complications. The median follow-up length 
was 22 months (range: 3 to 108 months), and the mean survival 
time was 73.8 months (Fig. 2).
Discussion
According to the ‘2009 Nationwide survey on surgically treated 
gastric cancer patients in South Korea’, the proportion of nodal me-
tastasis was 37.4%.(9) However, we found that a higher proportion 
of tumors with NEF showed lymph node metastasis (75.9%) and 
lymphatic invasion (82.8%). We compared these data with another 
study data of ‘Helicobacter pylori related gastric cancer’ which re-
ceived gastrectomy at our institute between January 2006 and De-
cember 2006. These result also showed NEF had more lymphatic 
or vascular invasion (Table 2). However theses data had limitation, 
which was difference of the time period between two groups. Kim 
et al.(10) suggest that there is a paracrine effect of tumor growth 
factor that is caused by neuroendocrine tumors. Eren et al.(11) also 
suggest that neuroendocrine cells may contribute to angiogenesis by 
expressing VEGF, especially in advanced stage cases. We noticed 
that there were more advanced stage tumors among the NEF group 
than the non-NEF group.(9) This finding was also observed in the 
study by Ooi et al.(4) for gastric carcinomas, Tamura et al.(12) for 
endometrial adenocarcinomas and Allen et al.(13) for prostatic ad-
enocarcinomas. Similar to these studies, we think that this is likely 
due to the expression of multi potent stem cells, which are more 
common in advanced stage tumors.
In our study, their mean survival time was 73.8 months and 
seven (24%) of them had died of disease within 2 years. Generally, 
the survival time was strongly correlated with tumor stage, however 
we did not have sufficient NEF data for individual stages to com-
pare survival time between NEF and non-NEF tumors.
We used two neuroendocrine markers, chromogranin A and 
synaptophysin. Chromogranin A is widely distributed in the secre-
tary granules of most polypeptide-producing endocrine tissues and 
is considered to be very useful as a diagnostic aid for normal neu-
roendocrine and tumor cells.(14) In our study, 62.5% of the NEF 
showed immunoreactivity for chromogranin A. Synaptophysin 
is an integral membrane glycoprotein that was originally isolated 
from bovine neuronal presynaptic vesicles and is considered to be a 







   Diff  use 12 (41.4%) 84 (44.4%)
   Intestinal 13 (44.8%)  75 (39.7%)
   Mixed 4 (13.8%) 30 (15.9%)
Lymphatic invasion 0.023
   Present 24 (82.8%) 115 (60.8%)
   Not identifi  ed 5 (17.2%) 74 (39.2%)
Vascular invasion <0.001
   Present 17 (58.6%) 21 (11.1%)
   Not identifi  ed 12 (41.4%) 168 (88.9%)
Neural invasion 0.675
   Present 11 (37.9%) 63 (33.3%)
   Not identifi  ed 18 (62.1%) 126 (66.7%)
*189 cases of non-NEF adenocarcinoma which received gastrectomy 
at the Department of Surgery, Ajou University Hospital between 
January 2006 and December 2006.  
Fig. 2. Kaplan-Meier survival curves of gastric adenocarcinoma with 
neuroendocrine features.Adenocarcinoma with Neuroendocrine Features
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significant neuroendocrine marker.(15) In our study, 76.5% of NEF 
were positive for synaptophysin. Therefore, both chromogranin A 
and synaptophysin have been shown to be valuable markers for 
detecting neuroendocrine cells. However, we did not perform this 
immunohistochemical stain for all tumor cells. Only 29 tumors had 
the exact diagnosis of NEF, although we performed more than 
two thousand gastrectomies. Eren et al.(11) found neuroendocrine 
differentiation in tumor cells among 45% of the conventional gas-
tric adenocarcinomas. Waldum et al.(16) suggested a correlation 
between diffuse-type gastric carcinomas and those with neuroen-
docrine differentiation. Compare with our another data (H. pylori 
related gastric cancer), NEF and non-NEF showed similar Lauren 
classification (Table 2).
In conclusion, NEF was more frequent in advanced stage gastric 
adenocarcinomas and was more commonly associated with lymph 
node metastasis. If preoperative biopsy show the presence of NEF 
in gastric adenocarcinomas should thus raise concern for lymph 
node metastasis, and a lymph node dissection should be completed 
in such patients.
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